{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:03:54Z","timestamp":1768035834476,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.biologicals.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T03:27:29Z","timestamp":1553311649000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Modifications of recombinant monoclonal antibodies in vivo"],"prefix":"10.1016","volume":"59","author":[{"given":"Hongcheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rekha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2019.03.006_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit'","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biologicals.2019.03.006_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.biologicals.2019.03.006_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","article-title":"Antibodies to watch in 2018","volume":"10","author":"Kaplon","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.biologicals.2019.03.006_bib5","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.biologicals.2019.03.006_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biologicals.2019.03.006_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.bi.19.070150.002205","article-title":"Chemical composition of blood plasma and serum","volume":"19","author":"Krebs","year":"1950","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14789450.2017.1352473","article-title":"Abundance matters: role of albumin in diabetes, a proteomics perspective","volume":"14","author":"Bhat","year":"2017","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.biologicals.2019.03.006_bib9","first-page":"561","article-title":"Nephelometric measurements of human IgG subclasses and their reference ranges","volume":"52","author":"Vlug","year":"1994","journal-title":"Ann Biol Clin(Paris)"},{"key":"10.1016\/j.biologicals.2019.03.006_bib10","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/acs.analchem.5b04276","article-title":"LC-MS\/MS-Based monitoring of in vivo protein biotransformation: quantitative determination of Trastuzumab and its deamidation products in human plasma","volume":"88","author":"Bults","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/ac0494174","article-title":"In vivo deamidation characterization of monoclonal antibody by LC\/MS\/MS","volume":"77","author":"Huang","year":"2005","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4155\/bio-2016-0035","article-title":"Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC-MS","volume":"8","author":"Mehl","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.biologicals.2019.03.006_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/mabs.24458","article-title":"Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule","volume":"5","author":"Ouellette","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib14","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1021\/acs.analchem.6b02766","article-title":"Automated affinity capture and on-tip digestion to accurately quantitate in vivo deamidation of therapeutic antibodies","volume":"88","author":"Tran","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/19420862.2016.1167298","article-title":"Assessing in vivo dynamics of multiple quality attributes from a therapeutic IgG4 monoclonal antibody circulating in cynomolgus monkey","volume":"8","author":"Li","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.biologicals.2009.06.001","article-title":"Human antibody Fc deamidation in vivo","volume":"37","author":"Liu","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2019.03.006_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/glycob\/cwr141","article-title":"Rates and impact of human antibody glycation in vivo","volume":"22","author":"Goetze","year":"2012","journal-title":"Glycobiology"},{"key":"10.1016\/j.biologicals.2019.03.006_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4161\/mabs.25269","article-title":"Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies","volume":"5","author":"Yang","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/bit.21260","article-title":"Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides","volume":"97","author":"Dick","year":"2007","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.biologicals.2019.03.006_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jpba.2006.05.008","article-title":"Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development","volume":"42","author":"Yu","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.biologicals.2019.03.006_bib21","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1021\/ac051827k","article-title":"Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies","volume":"78","author":"Chelius","year":"2006","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/19420862.2016.1186322","article-title":"Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies","volume":"8","author":"Li","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib23","doi-asserted-by":"crossref","first-page":"11211","DOI":"10.1074\/jbc.M110.185041","article-title":"N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11095-012-0860-z","article-title":"Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies","volume":"30","author":"Yin","year":"2013","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.biologicals.2019.03.006_bib25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1021\/bi951526c","article-title":"Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity","volume":"35","author":"Cacia","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.biologicals.2019.03.006_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0378-4347(00)00548-X","article-title":"Identification of multiple sources of charge heterogeneity in a recombinant antibody","volume":"752","author":"Harris","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.biologicals.2019.03.006_bib27","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1021\/bi7018223","article-title":"Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma 2 antibody highlights the role avidity plays in antibody activity","volume":"47","author":"Rehder","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.biologicals.2019.03.006_bib28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1021\/bi061500t","article-title":"Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies","volume":"46","author":"Wakankar","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.biologicals.2019.03.006_bib29","first-page":"117","article-title":"Heterogeneity of recombinant antibodies: linking structure to function","volume":"122","author":"Harris","year":"2005","journal-title":"Dev Biol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ab.2009.09.027","article-title":"Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the VH domain of an immunoglobulin G1 molecule","volume":"397","author":"Ouellette","year":"2010","journal-title":"Anal Biochem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib31","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1021\/ac301426h","article-title":"Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody","volume":"84","author":"Zhang","year":"2012","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib32","doi-asserted-by":"crossref","first-page":"29266","DOI":"10.1074\/jbc.M804787200","article-title":"Human IgG2 antibody disulfide rearrangement in vivo","volume":"283","author":"Liu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib33","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.biologicals.2019.03.006_bib34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.copbio.2014.09.001","article-title":"Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies","volume":"30","author":"Yang","year":"2014","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib36","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.4049\/jimmunol.170.6.3134","article-title":"Human IgG2 can form covalent dimers","volume":"170","author":"Yoo","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molimm.2013.11.011","article-title":"Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2","volume":"58","author":"Yang","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00290300","article-title":"Immunoglobulin G and serum albumin isolated from the articular cartilage of patients with rheumatoid arthritis or osteoarthritis contain covalent heteropolymers with proteoglycans","volume":"13","author":"Mannik","year":"1993","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.biologicals.2019.03.006_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchromb.2017.09.027","article-title":"Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: feasibility assessment for future mass spectrometry hyphenation","volume":"1065\u20131066","author":"Goyon","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.biologicals.2019.03.006_bib40","doi-asserted-by":"crossref","first-page":"34325","DOI":"10.1074\/jbc.M113.506915","article-title":"Cysteine racemization on IgG heavy and light chains","volume":"288","author":"Zhang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib41","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1021\/ac9006254","article-title":"Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody","volume":"81","author":"Pristatsky","year":"2009","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib42","doi-asserted-by":"crossref","first-page":"16371","DOI":"10.1074\/jbc.M113.468397","article-title":"IgG1 thioether bond formation in vivo","volume":"288","author":"Zhang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/glycob\/cwn120","article-title":"The effect of Fc glycan forms on human IgG2 antibody clearance in humans","volume":"19","author":"Chen","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.biologicals.2019.03.006_bib44","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"10.1016\/j.biologicals.2019.03.006_bib45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4161\/mabs.20450","article-title":"Increased serum clearance of oligomannose species present on a human IgG1 molecule","volume":"4","author":"Alessandri","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biologicals.2016.02.003","article-title":"Effect of high mannose glycan pairing on IgG antibody clearance","volume":"44","author":"Liu","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2019.03.006_bib47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2249.1993.tb08216.x","article-title":"Glycation increases the vascular clearance rate of IgG in mice","volume":"94","author":"Kennedy","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1208\/s12248-014-9694-4","article-title":"Impact of glycation on antibody clearance","volume":"17","author":"Yang","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.biologicals.2019.03.006_bib49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/bit.21855","article-title":"C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes","volume":"100","author":"Dick","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.biologicals.2019.03.006_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9673(94)01255-D","article-title":"Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture","volume":"705","author":"Harris","year":"1995","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.biologicals.2019.03.006_bib51","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/bit.22933","article-title":"C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo","volume":"108","author":"Cai","year":"2011","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.biologicals.2019.03.006_bib52","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1021\/bi702238b","article-title":"Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation","volume":"47","author":"Liu","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.biologicals.2019.03.006_bib53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.molimm.2007.07.012","article-title":"Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody","volume":"45","author":"Liu","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib54","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1021\/acs.analchem.6b01958","article-title":"Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen\/deuterium exchange mass spectrometry","volume":"88","author":"Mo","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.biologicals.2019.03.006_bib55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/pro.45","article-title":"Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn","volume":"18","author":"Pan","year":"2009","journal-title":"Protein Sci"},{"key":"10.1016\/j.biologicals.2019.03.006_bib56","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molimm.2010.12.009","article-title":"Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies","volume":"48","author":"Wang","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib57","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4161\/mabs.21328","article-title":"Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies","volume":"4","author":"Du","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib58","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4161\/mabs.2.6.13333","article-title":"Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats","volume":"2","author":"Khawli","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.biologicals.2019.03.006_bib59","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/jps.21180","article-title":"Heterogeneity of monoclonal antibodies","volume":"97","author":"Liu","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biologicals.2019.03.006_bib60","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/138920108786786402","article-title":"Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods","volume":"9","author":"Vlasak","year":"2008","journal-title":"Curr Pharmaceut Biotechnol"},{"key":"10.1016\/j.biologicals.2019.03.006_bib61","article-title":"Charge variants of an avastin biosimilar isolation, characterization, in vitro properties and pharmacokinetics in rat","volume":"11","author":"Zhao","year":"2016","journal-title":"PLoS One"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105618301210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105618301210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:13:49Z","timestamp":1760922829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105618301210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":61,"alternative-id":["S1045105618301210"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2019.03.006","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modifications of recombinant monoclonal antibodies in vivo","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}]}}